All these findings suggest the involvement of ADAM8, L-selectin, E-selectin, and PSGL-1 in the pathogenesis of both SLE and SSc and could be postulated as potential molecular targets for future therapy strategies. The gene discussed is SELL; the disease is systemic sclerosis.